Rational combinations using HDAC inhibitors

213Citations
Citations of this article
105Readers
Mendeley users who have this article in their library.

Abstract

In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs. Innumerous in vitro and preclinical settings, these compounds have shown their vast potential as single agent anticancer therapies, but unfortunately equivalent responses have not always been observed in patients. Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs. In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong molecular rationale. © 2009 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Bots, M., & Johnstone, R. W. (2009, June 15). Rational combinations using HDAC inhibitors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-08-2786

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free